Medicenna Therapeutics to Present at Upcoming March Investor Conferences
Medicenna Therapeutics announced that its CEO, Dr. Fahar Merchant, will present at three major investor conferences in March 2021. These include the H.C. Wainwright Global Life Sciences Conference on March 9, the Oppenheimer 31st Annual Healthcare Conference on March 17, and the Maxim 2021 Emerging Growth Virtual Conference also on March 17. The company's lead product, MDNA55, has shown promise in clinical trials for treating rGBM and has received FDA Fast-Track and Orphan Drug designations.
- None.
- None.
TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference, as well as participating in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference. All three virtual investor conferences will take place in March 2021.
Details are as follows:
H.C. Wainwright Global Life Sciences Conference
Format: Pre-Recorded Presentation
Date: Available on-demand starting at 7 am ET on Tuesday, March 9, 2021
Oppenheimer 31st Annual Healthcare Conference
Format: Live Presentation
Date: Wednesday, March 17
Time: 2:30 pm ET
Maxim 2021 Emerging Growth Virtual Conference
Format: Live Glioblastoma Panel Discussion and Pre-Recorded Presentation
Date: Wednesday, March 17
Time: 11:00 am ET
Webcast and replay links and further information for these events will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.
About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
Forward-looking statement
This news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects", "believes" and similar expressions. All statements other than statements of historical fact, included in this release, including the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form of the Company dated May 14, 2020 and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect and that study results could change over time as the study is continuing to follow up all subjects and new data are continually being received which could materially change study results. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian and United States securities law.
FAQ
When is Medicenna's presentation at the H.C. Wainwright Global Life Sciences Conference?
What are the details of Medicenna's participation in the Oppenheimer 31st Annual Healthcare Conference?
What will be discussed during Medicenna's session at the Maxim 2021 Emerging Growth Virtual Conference?
What key products is Medicenna developing?
What designations has MDNA55 received from the FDA?
